Loading
A phase 1/2 trial of Serplulimab in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Henlius Biotech, now recruiting.
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06848699 by Shanghai Henlius Biotech, with 105 participants planned, started 2025-02-25 and due to reach its primary completion in 2026-10-30. Interventions recorded: HLX43 dose 1, HLX43 dose 2, HLX43 dose 3, HLX43 dose 4, HLX43 dose 5. Conditions listed: Solid Tumor Cancer, Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/